New mRNA vaccine targets brain tumors in early trial
NCT ID NCT07306299
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a universal mRNA vaccine designed to target common mutations in high-grade glioma, a type of aggressive brain cancer. Ten patients with recurrent or progressive disease will receive the vaccine to see if it is safe and can stimulate an immune response against their tumors. The study will monitor side effects and tumor growth over three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mRNA vaccine targeting glioma mutations
- What this could lead to
- If it works, this could point toward a new treatment option for recurrent high-grade glioma by training the immune system to attack tumor cells.
- What could go wrong
- This is a very early Phase 1 trial with only 10 participants, so safety and effectiveness are not yet proven. The vaccine may not trigger a strong enough immune response or could cause side effects like brain swelling.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, HIGH GRADE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Room 521, Building 12, Jiefang Road Campus, The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.